AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900
Debt
Debt-to-Equity Ratio6.07%
Current Ratio1.28%
Quick Ratio1.18%
Price-To-Earnings
Trailing P/E Ratio16.54
Forward P/E Ratio12.23
P/E Growth0.89
Sales & Book Value
Annual Sales$28.22 billion
Price / Sales5.21
Cash Flow$6.5861 per share
Price / Cash14.06
Book Value$3.19 per share
Price / Book29.03
Profitability
EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins18.82%
Return on Equity158.15%
Return on Assets13.24%
Miscellaneous
Employees29,000
Outstanding Shares1,587,970,000
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Thursday, February 15th. Investors of record on Friday, April 13th will be given a dividend of $0.96 per share on Tuesday, May 15th. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.15%. The ex-dividend date of this dividend is Thursday, April 12th. This is a positive change from AbbVie's previous quarterly dividend of $0.71. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has authorized a share buyback program on Friday, February 16th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) posted its earnings results on Friday, January, 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.44 by $0.04. The business earned $7.74 billion during the quarter, compared to analysts' expectations of $7.53 billion. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The company's revenue was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie issued an update on its first quarter earnings guidance on Friday, January, 26th. The company provided EPS guidance of $1.77-1.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.49. AbbVie also updated its FY18 guidance to $7.33-7.43 EPS.
What price target have analysts set for ABBV?
16 analysts have issued 1-year target prices for AbbVie's stock. Their forecasts range from $80.00 to $157.00. On average, they anticipate AbbVie's stock price to reach $117.3333 in the next twelve months. View Analyst Ratings for AbbVie.
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares have outperformed the industry in the past year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals, including its competitive HCV medicine Mavyret and two approvals for Imbruvica and settlement of its Humira patent disputes with Amgen. In fact. Mavyret has become a major growth driver for AbbVie in a short time on the market. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, Viekira’s sales continue to be hurt by intensifying competition." (3/20/2018)
- 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Pfizer (PFE), Novartis (NVS), Merck & Co. (MRK), Novo Nordisk (NVO), Abbott Laboratories (ABT), Sanofi (SNY), Bayer (BAYRY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY) and Regeneron (REGN).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
- Mr. William J. Chase, Exec. VP & CFO (Age 50)
- Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
- Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)
Has AbbVie been receiving favorable news coverage?
Headlines about ABBV stock have trended positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of 0.30 on Accern's scale. They also gave news headlines about the company an impact score of 46.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $92.60.
How big of a company is AbbVie?
AbbVie has a market capitalization of $147.05 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
AbbVie (NYSE:ABBV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Their average twelve-month price target is $117.3333, suggesting that the stock has a possible upside of 26.71%. The high price target for ABBV is $157.00 and the low price target for ABBV is $80.00. There are currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.38 | 2.40 | 2.60 | 2.59 |
| Ratings Breakdown: | 1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $117.3333 | $115.7214 | $99.8571 | $93.25 |
| Price Target Upside: | 26.71% upside | 16.88% upside | 6.23% downside | 2.85% upside |
AbbVie (NYSE:ABBV) Consensus Price Target History
AbbVie (NYSE:ABBV) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
AbbVie (NYSE:ABBV) Dividend Information
AbbVie pays an annual dividend of $3.84 per share, with a dividend yield of 4.15%. ABBV's next quarterly dividend payment will be made on Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 15.50% each year. AbbVie pays out 68.57% of its earnings out as a dividend.
| Next Dividend: | 5/15/2018 |
| Annual Dividend: | $3.84 |
| Dividend Yield: | 4.15% |
| Dividend Growth: | 15.50% (3 Year Average) |
| Payout Ratio: | 68.57% (Trailing 12 Months of Earnings)
50.73% (Based on This Year's Estimates)
44.09% (Based on Next Year's Estimates)
|
| Track Record: | 45 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
AbbVie (NYSE:ABBV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/15/2018 | quarterly | $0.96 | 3.36252189141856% | 4/12/2018 | 4/13/2018 | 5/15/2018 |
| 10/27/2017 | Quarterly | $0.71 | 3.12% | 1/11/2018 | 1/12/2018 | 2/15/2018 |
| 9/8/2017 | Quarterly | $0.64 | 2.94% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/23/2017 | quarterly | $0.64 | 3.52% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.64 | 4.14% | 4/11/2017 | 4/13/2017 | 5/15/2017 |
| 10/28/2016 | quarterly | $0.64 | 4.44% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/12/2016 | quarterly | $0.57 | 3.56% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/17/2016 | quarterly | $0.57 | 3.8% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.57 | 4.2% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 11/2/2015 | quarterly | $0.57 | 3.6% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/14/2015 | quarterly | $0.51 | 3.46% | 10/13/2015 | 10/15/2015 | 11/14/2015 |
| 6/19/2015 | quarterly | $0.51 | 2.94% | 7/13/2015 | 7/15/2015 | 8/14/2015 |
| 2/20/2015 | quarterly | $0.51 | 3.33% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.48% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/19/2014 | quarterly | $0.42 | 2.86% | 10/10/2014 | 10/15/2014 | 11/17/2014 |
| 6/19/2014 | quarterly | $0.42 | 3.15% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/20/2014 | quarterly | $0.42 | 3.29% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 12/12/2013 | quarterly | $0.40 | 3.06% | 1/13/2014 | 1/15/2014 | 2/14/2014 |
| 9/19/2013 | quarterly | $0.40 | 3.34% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/20/2013 | quarterly | $0.40 | 3.75% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.40 | 4.19% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 1/7/2013 | special | $0.40 | | 1/11/2013 | 1/15/2013 | 2/15/2013 |
| 1/4/2013 | quarterly | $0.40 | | | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 70.57%
AbbVie (NYSE ABBV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Carlos Alban | EVP | Sell | 83,574 | $114.49 | $9,568,387.26 | 133,026 |  |
| 3/1/2018 | Laura J Schumacher | Insider | Sell | 25,000 | $117.85 | $2,946,250.00 | 123,317 | |
| 3/1/2018 | William J Chase | CFO | Sell | 70,928 | $117.18 | $8,311,343.04 | 203,391 | |
| 2/28/2018 | Richard A Gonzalez | Chairman | Sell | 8,280 | $117.88 | $976,046.40 | 321,292 | |
| 2/28/2018 | Robert A Michael | VP | Sell | 4,294 | $119.43 | $512,832.42 | 11,170 | |
| 2/28/2018 | Timothy J Richmond | SVP | Sell | 18,129 | $118.67 | $2,151,368.43 | 35,717 | |
| 2/20/2018 | Robert A Michael | VP | Sell | 992 | $120.31 | $119,347.52 | | |
| 12/18/2017 | Timothy J Richmond | SVP | Sell | 87,040 | $98.45 | $8,569,088.00 | 113,118 | |
| 12/15/2017 | Laura J Schumacher | Insider | Sell | 145,510 | $96.71 | $14,072,272.10 | | |
| 11/21/2017 | Richard A Gonzalez | Chairman | Sell | 218,193 | $94.01 | $20,512,323.93 | 492,030 | |
| 11/10/2017 | Michael Severino | EVP | Sell | 25,633 | $94.69 | $2,427,188.77 | 114,922 | |
| 10/30/2017 | Henry O Gosebruch | Insider | Sell | 18,300 | $90.55 | $1,657,065.00 | 81,287 | |
| 9/28/2017 | Robert A Michael | VP | Sell | 6,699 | $88.00 | $589,512.00 | 10,007 | |
| 9/11/2017 | Azita Saleki-Gerhardt | SVP | Sell | 8,300 | $85.02 | $705,666.00 | 93,099 | |
| 8/7/2017 | Richard A Gonzalez | Chairman | Sell | 193,131 | $71.00 | $13,712,301.00 | 469,623 | |
| 8/4/2017 | Richard A Gonzalez | Chairman | Sell | 87,899 | $71.02 | $6,242,586.98 | 342,353 | |
| 8/3/2017 | Richard A Gonzalez | CEO | Sell | 65,861 | $71.00 | $4,676,131.00 | 342,353 | |
| 7/31/2017 | Edward J Rapp | Director | Buy | 4,000 | $70.45 | $281,800.00 | 15,498 | |
| 7/31/2017 | Henry O Gosebruch | Insider | Sell | 18,000 | $70.09 | $1,261,620.00 | 96,074 | |
| 6/14/2017 | Carlos Alban | EVP | Sell | 45,800 | $70.00 | $3,206,000.00 | 160,545 | |
| 6/14/2017 | Laura J Schumacher | Insider | Sell | 79,800 | $70.00 | $5,586,000.00 | 187,625 | |
| 5/19/2017 | Richard A Gonzalez | Chairman | Sell | 71,235 | $65.49 | $4,665,180.15 | 349,462 | |
| 5/18/2017 | William J Chase | CFO | Sell | 38,300 | $65.35 | $2,502,905.00 | 209,043 | |
| 5/4/2017 | Carlos Alban | EVP | Sell | 43,000 | $67.00 | $2,881,000.00 | 114,745 | |
| 3/10/2017 | Laura J Schumacher | Insider | Sell | 40,000 | $65.26 | $2,610,400.00 | 147,415 | |
| 3/10/2017 | Robert A Michael | VP | Sell | 5,132 | $65.29 | $335,068.28 | 16,706 | |
| 3/10/2017 | Timothy J Richmond | SVP | Sell | 22,451 | $65.29 | $1,465,825.79 | 26,078 | |
| 3/8/2017 | Richard A Gonzalez | Chairman | Sell | 72,016 | $64.25 | $4,627,028.00 | 369,113 | |
| 12/2/2016 | William J Chase | CFO | Sell | 6,600 | $59.19 | $390,654.00 | 178,970 | |
| 9/7/2016 | Laura J Schumacher | Insider | Sell | 50,000 | $65.00 | $3,250,000.00 | 144,138 | |
| 6/24/2016 | Laura J Schumacher | EVP | Sell | 186,106 | $60.03 | $11,171,943.18 | 260,438 | |
| 6/2/2016 | Richard A Gonzalez | CEO | Sell | 285,953 | $63.82 | $18,249,520.46 | 624,374 | |
| 5/11/2016 | Richard A Gonzalez | CEO | Sell | 39,000 | $63.80 | $2,488,200.00 | 338,421 | |
| 5/10/2016 | Carlos Alban | EVP | Sell | 47,438 | $63.52 | $3,013,261.76 | 149,444 | |
| 5/10/2016 | Thomas A Hurwich | VP | Sell | 6,000 | $63.59 | $381,540.00 | 68,204 | |
| 5/10/2016 | Timothy J Richmond | SVP | Sell | 21,583 | $63.52 | $1,370,952.16 | 44,615 | |
| 3/8/2016 | Laura J Schumacher | EVP | Sell | 25,000 | $56.09 | $1,402,250.00 | 199,238 | |
| 3/1/2016 | Timothy J Richmond | SVP | Sell | 12,866 | $55.05 | $708,273.30 | 79,064 | |
| 4/28/2015 | Richard A Gonzalez | CEO | Sell | 102,964 | $64.67 | $6,658,681.88 | | |
| 3/2/2015 | Laura J Schumacher | EVP | Sell | 25,000 | $60.30 | $1,507,500.00 | | |
| 3/2/2015 | Timothy J Richmond | SVP | Sell | 14,388 | $60.33 | $868,028.04 | | |
| 12/22/2014 | William J Chase | CFO | Sell | 8,495 | $68.00 | $577,660.00 | | |
| 3/4/2014 | Richard Gonzalez | CEO | Sell | 4,799 | $51.20 | $245,708.80 | 395,403 | |
| 3/3/2014 | Azita Saleki-Gerhardt | SVP | Sell | 2,443 | $50.25 | $122,760.75 | 85,828 | |
| 3/3/2014 | Carlos Alban | EVP | Sell | 2,882 | $50.09 | $144,359.38 | 205,138 | |
| 3/3/2014 | William Chase | CFO | Sell | 3,948 | $50.22 | $198,268.56 | 180,068 | |
| 9/17/2013 | Azita Saleki-Gerhardt | SVP | Sell | 10,473 | $45.84 | $480,082.32 | 66,703 | |
| 8/19/2013 | Azita Saleki-Gerhardt | SVP | Sell | 1,270 | $43.01 | $54,622.70 | 64,279 | |
| 8/12/2013 | Azita Saleki-Gerhardt | SVP | Sell | 8,851 | $44.91 | $397,498.41 | 64,237 | |
| 3/11/2013 | Edward J Rapp | Director | Buy | 2,500 | $37.67 | $94,175.00 | | |
| 2/4/2013 | Frederick H Waddell | Director | Buy | 2,000 | $37.05 | $74,100.00 | | |
(Data available from 1/1/2013 forward)
AbbVie (NYSE ABBV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices
seekingalpha.com - April 21 at 3:10 PM |
 | AbbVie And Other Great Pharma And Biotech Income Stocks
finance.yahoo.com - April 20 at 3:10 PM |
 | AbbVie (ABBV) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 20 at 12:58 AM |
 | Bari Adcom Negative for Eli Lilly (LLY) and AbbVie (ABBV), Positive for Pfizer (PFE) - BMO
www.streetinsider.com - April 19 at 3:11 PM |
| Novartis Q1 results weigh on pharma stocks
seekingalpha.com - April 19 at 3:11 PM |
| AbbVie Inc. (ABBV) to Post Q4 2018 Earnings of $1.93 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 19 at 7:14 AM |
| AbbVie Inc. Forecasted to Post Q2 2018 Earnings of $1.89 Per Share (ABBV)
www.americanbankingnews.com - April 19 at 6:38 AM |
| Roche Hemophilia Drug Gets Breakthrough Therapy Designation
finance.yahoo.com - April 19 at 5:16 AM |
| Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising
finance.yahoo.com - April 19 at 5:16 AM |
| AbbVie (ABBV) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:21 AM |
| Analysts’ Recommendations for AbbVie in April 2018
finance.yahoo.com - April 18 at 3:10 PM |
| AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference
finance.yahoo.com - April 18 at 3:10 PM |
| AbbVie Inc. to Post Q4 2018 Earnings of $2.08 Per Share, William Blair Forecasts (ABBV)
www.americanbankingnews.com - April 18 at 8:39 AM |
| AbbVie Inc. to Post Q1 2018 Earnings of $1.85 Per Share, Leerink Swann Forecasts (ABBV)
www.americanbankingnews.com - April 18 at 8:13 AM |
| SunTrust Banks Weighs in on AbbVie Inc.'s Q1 2018 Earnings (ABBV)
www.americanbankingnews.com - April 18 at 7:58 AM |
| DEA aims to collar production of opioids
seekingalpha.com - April 18 at 5:07 AM |
| Sen. Sanders introduces bill to fine opioid makers for marketing practices
seekingalpha.com - April 18 at 5:07 AM |
 | Top Analyst Reports for AbbVie, Berkshire & PepsiCo
www.zacks.com - April 17 at 3:14 PM |
| Updates on AbbVie’s AndroGel, Lupron, and Kaletra
finance.yahoo.com - April 17 at 3:14 PM |
| 5 Drug Stocks Poised to Surpass on Earnings This Quarter
finance.yahoo.com - April 17 at 3:14 PM |
| Novartis’s 1Q18: Analysts Expect Revenue Growth
finance.yahoo.com - April 17 at 3:14 PM |
| 7 Stock Picks With Giant Upside: Goldman
finance.yahoo.com - April 17 at 3:14 PM |
 | AbbVie Inc. Is a Clear Value Play in Biotech Stocks
investorplace.com - April 17 at 12:27 PM |
| Q3 2018 EPS Estimates for AbbVie Inc. Lowered by Analyst (ABBV)
www.americanbankingnews.com - April 17 at 6:41 AM |
| Upadacitinib Could Drive AbbVie’s Long-Term Growth
finance.yahoo.com - April 16 at 3:19 PM |
 | Global Microbiome Therapeutics Market Overview 2017-2026: AbbVie Inc., Ganeden, Johnson and Johnson
www.marketwatch.com - April 16 at 5:30 AM |
| Brokers Set Expectations for AbbVie Inc.'s FY2018 Earnings (ABBV)
www.americanbankingnews.com - April 16 at 2:33 AM |
| AbbVie Inc. (ABBV) Forecasted to Earn Q1 2018 Earnings of $1.81 Per Share
www.americanbankingnews.com - April 16 at 1:50 AM |
| AbbVie (ABBV) Upgraded at Vetr
www.americanbankingnews.com - April 15 at 11:43 PM |
| AbbVie (ABBV) PT Set at $70.00 by Cowen
www.americanbankingnews.com - April 15 at 9:46 AM |
| Piper Jaffray Reiterates "Buy" Rating for AbbVie (ABBV)
www.americanbankingnews.com - April 13 at 3:17 PM |
| Exploring Voyager Therapeutics’ Research Pipeline
finance.yahoo.com - April 13 at 3:13 PM |
| AbbVie (ABBV) PT Set at $122.00 by Jefferies Group
www.americanbankingnews.com - April 13 at 10:13 AM |
| Mylan secures exclusive rights to Humira biosimilar in Europe
seekingalpha.com - April 12 at 3:09 PM |
| AbbVie Stock Is Signaling That a Move to the Upside Could Be Near
finance.yahoo.com - April 12 at 3:09 PM |
 | BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain
www.reuters.com - April 11 at 3:14 PM |
 | AbbVie's RA Candidate Meets Primary Endpoints in Phase III
www.msn.com - April 11 at 3:14 PM |
| FDA Prolongs Review Date for AbbVie Endometriosis Candidate
finance.yahoo.com - April 11 at 3:13 PM |
| AbbVie (ABBV) Given a $109.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 11 at 7:35 AM |
 | Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie
www.nasdaq.com - April 10 at 3:01 PM |
 | AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis ...
www.prnewswire.com - April 10 at 3:01 PM |
| FDA extends action date to Q3 for review of AbbVie's elagolix application
seekingalpha.com - April 10 at 10:20 AM |
| AbbVie Looks To Upadacitinib To Protect Itself From Humira Patent Loss
seekingalpha.com - April 10 at 5:04 AM |
| 3 Things In Biotech, April 8: Incyte's Crash, AbbVie's Coup, Mologen's Coming
seekingalpha.com - April 9 at 3:14 PM |
| Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
finance.yahoo.com - April 9 at 3:14 PM |
| AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial
finance.yahoo.com - April 9 at 3:14 PM |
 | Here's Why AbbVie Inc. Fell 18.3% in March
www.fool.com - April 9 at 5:13 AM |
| Here's Why AbbVie Inc. Fell 18.3% in March
finance.yahoo.com - April 9 at 5:13 AM |
| AbbVie Inc. (ABBV) Expected to Announce Quarterly Sales of $7.58 Billion
www.americanbankingnews.com - April 9 at 3:44 AM |
| AbbVie (ABBV) Price Target Raised to $115.00
www.americanbankingnews.com - April 7 at 12:39 PM |
AbbVie (NYSE:ABBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement
AbbVie (NYSE ABBV) Stock Chart for Sunday, April, 22, 2018
Loading chart…
